China NMPA Product Recall - Pediatric oxygenation system

Medtronic (Shanghai) Management Co., Ltd. has initiated a voluntary Level 1 recall of its pediatric oxygenation systems (Model BBP241, Registration Certificate No.: 20183102418). This action, reported by the Shanghai Municipal Drug Administration and overseen by the National Medical Products Administration (NMPA), addresses a critical product defect. During routine testing and proactive investigation, Medtronic identified that certain units manufactured between April 2, 2020, and October 2, 2020, contained excessive levels of endotoxins. The estimated probability of this issue occurring in affected products is 1.5%. The primary concern associated with using these non-conforming systems is the potential for serious health complications, including fever, infection, or acute systemic toxicity in pediatric patients. As of January 2021, Medtronic had not received any global complaints related to this specific issue, including within the domestic market. The company is taking proactive measures to mitigate patient risk by recalling the affected devices. Detailed information regarding the specific models, specifications, and batch numbers subject to this recall is available in the "Medical Device Recall Event Report Form," which stakeholders are directed to consult for comprehensive guidance on required actions. This recall underscores Medtronic's commitment to patient safety and adherence to NMPA regulatory standards.